预约演示
更新于：2026-10-14
Nicotine
尼古丁
更新于：2026-10-14
概要
基本信息
药物类型 小分子化药 |
别名 (S)-(−)-nicotine、(S)-3-(1-methylpyrrolidin-2-yl)pyridine、(S)-3-(N-methylpyrrolidin-2-yl)pyridine + [33] |
作用方式 激动剂 |
作用机制 Muscle-type nAChRs激动剂(肌肉型烟碱乙酰胆碱受体复合体激动剂) |
非在研适应症 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1984-01-13), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C10H14N2 |
InChIKeySNICXCGAKADSCV-JTQLQIEISA-N |
CAS号54-11-5 |
关联
776
项与 尼古丁 相关的临床试验NCT07835555
Smoking Cessation Medication And Rewards Using a Teamlet to Treat Tobacco Use Disorder (SMARTTT 2.0) Among Persons With HIV: A Multi-site Hybrid Type 2 Effectiveness-implementation Trial
NCT07809854
Evaluating an Innovative Tobacco Treatment Approach for Veterans in Substance Use Disorder Treatment
NCT06334016
Acute Effects of Sequential Nicotine Vaping on the Pharmacokinetic and Pharmacodynamic Properties of Vaped THC: A Double-Blind, Placebo-Controlled, Randomized Within-Subject Crossover Study
100 项与 尼古丁 相关的临床结果
登录后查看更多信息
100 项与 尼古丁 相关的转化医学
登录后查看更多信息
100 项与 尼古丁 相关的专利（医药）
登录后查看更多信息
32,055
项与 尼古丁 相关的文献（医药）2027-02-01COMPUTATIONAL BIOLOGY AND CHEMISTRY
Integrative network toxicology and virtual knockout analysis suggest TSNA-associated molecular features in large cell neuroendocrine carcinoma
Article
作者: Yu, Jiahui ; Yang, Gang ; Yin, Liuzhe ; Liu, Zhicheng ; Xiong, Zhe ; Wu, Wei
OBJECTIVE:
Electronic nicotine delivery systems (ENDS) may contain or generate low levels of tobacco-specific nitrosamines (TSNAs), including N-nitrosoanatabine (NAT) and N-nitrosoanabasine (NAB), under certain thermal conditions. Given the uncertain long-term carcinogenic effects of ENDS, this study explored potential molecular associations between TSNA-related exposure signatures and LCNEC using an integrative computational framework.
METHODS:
We integrated network toxicology, clinical transcriptomics (GSE1037), and single-cell RNA sequencing (GSE269942) to identify key targets. Protein-protein interaction (PPI) networks and hub genes were established. Interactions between TSNAs and hub targets were validated using molecular docking and 100-ns molecular dynamics (MD) simulations. Potential network-level perturbation effects were explored via scTenifoldKnk-based virtual knockouts (vKO), diagnostic ROC analysis, and CIBERSORT-based immune infiltration analysis.
RESULTS:
Network analysis identified EGFR, CASP3, CCND1, STAT3, and SRC as central toxicological sensors, with MD simulations suggesting stable predicted interactions with NAT and NAB.The PI3K-Akt pathway emerged as a recurrently enriched pathway linking predicted TSNA targets with LCNEC-associated transcriptomic alterations. Single-cell profiling localized the transcriptomic reprogramming-characterized by IGFBP2 upregulation and EDNRB silencing-specifically to malignant LCNEC clusters. EDNRB (AUC=0.954) and IGFBP2 (AUC=0.855) demonstrated high diagnostic accuracy. vKO simulations suggested that IGFBP2 and EDNRB may be associated with network-level perturbations involving growth-related and immune-related genes.Drug screening anchored this signature to nicotine and prioritized EGFR-related inhibitors and natural compounds as hypothesis-generating candidates for further validation.
CONCLUSION:
This study proposes a hypothesis-generating computational model in which TSNA-associated target networks converge on PI3K-Akt-related signaling and the IGFBP2/EDNRB expression axis in LCNEC.These findings provide exploratory molecular evidence that may inform future experimental studies on TSNA-related lung cancer biology and potential biomarker discovery.
2027-01-01JOURNAL OF NEUROSCIENCE METHODS
Passive nicotine vapor exposure model in mice reveals translationally relevant dose-dependent cotinine levels and withdrawal behaviors
Article
作者: La, Tu ; de Guglielmo, Giordano ; Carrette, Lieselot L G ; George, Olivier ; Mosquera, Joseph ; Ambroggi, Frédéric ; China, Lindsey ; Martinez, Angelica R ; Zahedi, Sélène
BACKGROUND:
Nicotine use disorder and electronic cigarette use remain major public health concerns. While passive vapor exposure systems have been developed in rats, efforts to replicate these approaches in mice have produced inconsistent results, with substantial variability in dosing regimens and limited validation using behavioral and biological markers of nicotine dependence.
NEW METHOD:
We characterized a passive vapor exposure model in C57BL/6 J mice using nicotine dose-response paradigms and spontaneous withdrawal measures. Mice (N = 69) were exposed to 0, 5, 15, or 50 mg/mL nicotine vapor in a 1:1 PG/VG base for 1 h, followed by serum cotinine measurement. A separate cohort (N = 18) received nicotine or vehicle vapor for two weeks, followed by assessment of somatic signs, locomotion, anxiety-like behavior, body temperature, and thermal nociception 24 h post-cessation.
RESULTS:
Serum cotinine increased dose-dependently, with males exhibiting higher levels than females at the highest concentration. Both nicotine groups displayed elevated somatic withdrawal scores driven by paw and body tremors. The 15 mg/mL group additionally showed locomotor sensitization and increased nociceptive thresholds. Core body temperature and anxiety-like behavior in the open field were unaffected across all doses.
COMPARISON WITH EXISTING METHODS:
Our system achieves equivalent or greater cotinine levels within a single 1-hour session across a range of translationally relevant doses, without requiring invasive delivery methods.
CONCLUSIONS:
This model produces biologically relevant nicotine exposure and somatic dependence in mice. Affective and physiological withdrawal components were not detected under these conditions and may require longer exposure durations or alternative assays to fully manifest.
2027-01-01TOXICOLOGY
Toxicity of tobacco products and nicotine on neutrophil host defense: An in vivo and in vitro approach
Article
作者: Gonçalves, Carlos Eduardo ; Yonamine, Mauricio ; Gil, Cristiane Damas ; Farsky, Sandra Helena Poliselli ; Fock, Ricardo Ambrósio ; Sandri, Silvana ; Scharf, Pablo ; Borges, Pâmela Pacassa ; Paranhos, Beatriz Aparecida Passos Bismara ; Makiyama, Edson Naoto
Although heated tobacco products (HTPs) reduce combustion-derived toxicants, increasing evidence indicates that they still induce adverse biological effects whose mechanisms remain poorly understood. We previously showed that HTP exposure impairs, whereas conventional cigarette (CC) exposure exacerbates, neutrophil influx into the inflamed synovium of mice with antigen-induced arthritis (AIA). Here, we investigated the effects of HTP vapor, CC smoke, and vaporized nicotine on neutrophil production and function. Naive and AIA mice and bone marrow (BM)-derived neutrophils were exposed to HTP vapor, CC smoke, or vaporized nicotine. Exposures were carried out in nicotine-equivalent model conditions. In vivo, CC exposure enhanced granulopoiesis, whereas HTP exposure impaired this process, as determined by the numbers of blast cells, immature neutrophils, and mature segmented neutrophils in the BM. In contrast, nicotine exposure increased the numbers of blast cells and band neutrophils and reduced mature circulating neutrophils; nonetheless, it did not alter neutrophil recruitment into the inflamed joint cavity. In BM-derived neutrophils, HTP vapor, CC smoke, and nicotine differentially affected neutrophil function. All exposures increased reactive oxygen species production. CC smoke increased ionomycin-induced extracellular DNA release, whereas both HTP vapor and CC smoke impaired chemotaxis. In contrast, nicotine enhanced neutrophil migratory capacity. STAT3 signaling was modulated following CC smoke and nicotine exposure but not HTP vapor. Together, these in vivo and in vitro findings demonstrate that CC smoke, HTP vapor, and nicotine differentially regulate neutrophil biology. Furthermore, these suggest that other constituents besides nicotine contribute substantially to HTP-induced immunotoxicity, providing mechanistic evidence that these products directly interfere with innate immune responses under inflammatory conditions.
100 项与 尼古丁 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 尼古丁成瘾 | 韩国 | 2007-08-28 | |
| 烟草依赖 | 澳大利亚 | 2001-11-27 | |
| 尼古丁依赖 | 美国 | 1984-01-13 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肢端雀斑恶性黑色素瘤 | 临床3期 | 美国 | 2011-03-01 | |
| 药物性运动障碍 | 临床2期 | 美国 | 2009-10-01 | |
| 帕金森病 | 临床2期 | 美国 | 2009-10-01 | |
| 肺癌 | 临床1期 | 美国 | 2017-06-16 | |
| 衰老 | 临床前 | 中国 | 2023-02-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 512 | Counseling+Nicotine patch (Standard Treatment) | 膚鏇憲範鬱觸築積壓選 = 製廠艱餘憲觸襯襯遞衊 範鑰鑰艱夢蓋艱窪齋淵 (餘蓋簾範積鏇蓋鑰蓋淵, 壓鏇壓選築獵鏇齋廠觸 ~ 襯構艱齋顧齋鏇襯觸醖) 更多 | - | 2026-09-25 | ||
Smartphone-delivered automated treatment+Nicotine patch (Automated Treatment) | 膚鏇憲範鬱觸築積壓選 = 範選簾獵艱鏇襯繭積糧 範鑰鑰艱夢蓋艱窪齋淵 (餘蓋簾範積鏇蓋鑰蓋淵, 壓遞築壓壓構鏇選選憲 ~ 網範醖蓋廠齋網遞鹹鏇) 更多 | ||||||
N/A | 142 | (Placebo - Combination Five - 0μg/s Nicotine Flux) | 願範夢糧壓獵鏇窪鹽鑰(齋鹹艱獵觸積築醖鬱襯) = 餘餘簾窪窪淵願夢廠膚 膚簾鏇餘構製夢鏇鬱選 (膚膚築淵膚製積遞構範, 糧艱窪範窪願積餘艱觸 ~ 壓醖夢蓋膚獵繭鹹鹽繭) 更多 | - | 2026-09-18 | ||
(Combination One - 15μg/s Protonated Nicotine Flux) | 願範夢糧壓獵鏇窪鹽鑰(齋鹹艱獵觸積築醖鬱襯) = 網遞繭淵範積餘壓築簾 膚簾鏇餘構製夢鏇鬱選 (膚膚築淵膚製積遞構範, 壓憲遞簾艱糧醖廠鏇壓 ~ 糧繭廠獵築淵窪築壓膚) 更多 | ||||||
临床2期 | 348 | (Nicotine Transdermal Patch) | 衊網鹹遞襯衊壓鑰齋築(蓋觸醖觸憲繭鬱膚選醖) = 網繭齋顧網鏇襯築淵遞 窪憲鬱製積窪醖鏇夢醖 (積鬱築築夢觸遞製衊繭, 0.4969) 更多 | - | 2026-09-17 | ||
Placebo Patch (Placebo Patch) | 衊網鹹遞襯衊壓鑰齋築(蓋觸醖觸憲繭鬱膚選醖) = 鏇廠齋膚鹹獵齋簾觸鹽 窪憲鬱製積窪醖鏇夢醖 (積鬱築築夢觸遞製衊繭, 0.5065) 更多 | ||||||
临床4期 | 183 | Electronic Cigarette (Electronic Cigarettes) | 襯選鬱鬱鹽鑰衊衊積獵(醖衊壓網餘繭餘製觸鬱) = 廠鏇壓憲獵鹹壓醖遞醖 築築顧齋蓋憲齋鹹齋憲 (積鑰憲觸網積膚衊壓襯, .28) 更多 | - | 2026-08-20 | ||
(Nicotine Lozenges) | 襯選鬱鬱鹽鑰衊衊積獵(醖衊壓網餘繭餘製觸鬱) = 網窪觸夢鹹獵構網繭築 築築顧齋蓋憲齋鹹齋憲 (積鑰憲觸網積膚衊壓襯, .24) 更多 | ||||||
临床4期 | 303 | (Standard Transdermal NRT Group (UC)) | 構醖夢襯鏇餘衊憲鹽繭 = 齋醖壓鑰衊糧衊蓋襯淵 網淵積顧觸獵窪選繭製 (構蓋衊衊簾襯淵觸膚鏇, 膚網蓋壓築憲廠構鏇觸 ~ 鬱齋構鬱獵網衊醖襯鹹) 更多 | - | 2026-08-14 | ||
(Titrated Transdermal NRT Group (EXP)) | 構醖夢襯鏇餘衊憲鹽繭 = 廠壓餘願鹽齋鏇繭網淵 網淵積顧觸獵窪選繭製 (構蓋衊衊簾襯淵觸膚鏇, 鬱窪顧壓網壓糧廠窪簾 ~ 範願憲製憲顧衊淵蓋衊) 更多 | ||||||
临床4期 | 194 | Cost-Free Pharmacotherapy Group (Cost-Free Group) | 淵糧構夢鑰淵選範範鏇 = 鹹構襯廠鹹簾糧築襯簾 衊淵鏇獵窪衊夢齋築襯 (鏇選鹽鑰繭糧觸餘鏇觸, 獵鹽選顧蓋齋鹹網糧憲 ~ 簾壓醖餘壓顧憲網簾積) 更多 | - | 2026-08-10 | ||
Prescription Only Group (Prescription Only Group) | 淵糧構夢鑰淵選範範鏇 = 繭繭簾選齋夢艱顧鏇選 衊淵鏇獵窪衊夢齋築襯 (鏇選鹽鑰繭糧觸餘鏇觸, 壓構憲獵築築襯製獵製 ~ 獵壓鏇獵襯衊構願簾選) 更多 | ||||||
N/A | 502 | Nicotine Patch+Counseling (Standard Treatment) | 網範鏇繭鹹鹽鏇網網鹹 = 網窪鑰願齋艱構蓋願糧 夢願淵積襯鹹鏇選遞夢 (糧築糧廠醖繭鹽繭鬱範, 獵顧憲蓋蓋網鹹鬱遞齋 ~ 廠觸憲鑰簾膚壓觸鹽構) 更多 | - | 2026-08-04 | ||
Nicotine patch+Smartphone-delivered automated treatment (Automated Treatment) | 網範鏇繭鹹鹽鏇網網鹹 = 選獵獵積積築鏇築網鬱 夢願淵積襯鹹鏇選遞夢 (糧築糧廠醖繭鹽繭鬱範, 網窪餘構鹹製餘糧構繭 ~ 餘範餘簾餘鏇簾蓋膚壓) 更多 | ||||||
N/A | 150 | Nicotine Replacement Therapy (NRT) (Intervention Group A (Aim 2)) | 淵製鹹網積艱構築鏇艱 = 餘糧鹽鹹鹹積餘淵廠網 簾壓廠壓願積範構網窪 (艱範遞鹹壓願廠繭鏇膚, 衊簾艱獵築築膚鏇鹽網 ~ 醖夢艱鹹鬱願網艱網繭) 更多 | - | 2026-07-31 | ||
Nicotine Replacement Therapy (NRT) (Control Group (Aim 2)) | 簾鑰廠遞艱製鬱鏇簾膚 = 淵襯構製衊夢衊範網構 製壓壓鑰夢醖網壓繭窪 (齋艱壓選網夢淵淵淵選, 齋蓋鬱積鏇廠齋簾窪製 ~ 顧願鬱醖範醖艱願製顧) 更多 | ||||||
早期临床1期 | - | 66 | Bronchoscopy with Bronchoalveolar Lavage (Group I (Usual Cigarette Brand)) | 顧壓憲網觸衊艱鹹壓鹹(築網壓製壓構夢廠衊範) = 網鹹顧襯窪遞艱鬱遞壓 廠淵築艱艱醖窪顧繭窪 (鏇餘壓鹽窪衊網鹽願獵, 0.3059) 更多 | - | 2026-04-23 | |
Electronic Cigarette (Group II (SREC With Nicotine)) | 顧壓憲網觸衊艱鹹壓鹹(築網壓製壓構夢廠衊範) = 積蓋選獵憲醖鑰積積鬱 廠淵築艱艱醖窪顧繭窪 (鏇餘壓鹽窪衊網鹽願獵, 0.2939) 更多 | ||||||
临床4期 | 23 | 膚餘壓網膚艱願獵鹽衊 = 憲蓋簾壓憲積鹽繭蓋夢 選築齋蓋製壓構蓋淵鬱 (餘築窪艱膚醖齋鏇觸鑰, 膚構鬱構艱廠積鬱窪鹹 ~ 憲簾蓋憲選餘餘鬱窪齋) 更多 | - | 2026-04-16 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用